Sciencepulse

Psychedelic Therapy Is Back, but the Evidence Is Still Catching Up

Health Tech·November 9, 2026

Few drugs have had a stranger path through American science than psychedelics. In the 1960s, LSD, psilocybin and mescaline became symbols of the counterculture, and by the end of the decade restrictions had pushed most legitimate research out of the lab. For a long time, these compounds were more likely to appear in stories about youth rebellion than in discussions of medicine.

In a recent episode of Scientific American's Science Quickly podcast, host Rachel Feltman and science journalist Jane C. Hu trace that arc from the hippie movement to the current idea that psychedelics could be a cure-all for mental illness. The more useful question they raise is how much of that enthusiasm the evidence actually supports.

The honest answer is that the research is promising but unfinished. Clinical studies have reported encouraging results for depression, anxiety and addiction, especially when a drug session is paired with structured psychotherapy. But many trials are small, and it is often obvious to participants whether they received the active compound. That makes it hard to separate the drug's effect from expectation, the therapist's influence and the setting. Long-term safety, the right dosing and the people who should avoid these drugs are still open questions.

Politics has moved faster than the lab work. Recommended reading that accompanies the episode points to public comments from RFK Jr. describing ibogaine as holding unprecedented promise for treating depression, and to reports that psychedelics have been put on a fast track toward FDA review and approval. Supporters argue that speeding up approval could help patients who have run out of options. Skeptics counter that a faster timeline can compress the scrutiny that a drug with powerful psychological effects needs.

That tension is the story to watch. Faster approvals could bring more money and more trials, which is good for the field. But the questions that matter most, such as whether benefits hold up over months and whether therapy-supported treatment can be delivered safely outside research centers, take time to answer. Readers should treat headlines about psychedelic cures with the same caution they would give any early-stage treatment, and wait for the trial data and regulators to catch up with the rhetoric.